Product Availability: In Stock (FedEx delivery within 2 business days).
Ordering: To place an order please use Add to Cart button (account not required).
Transfection Reagent for NTERA-2 Cells (Embryonal Carcinoma Cells, CRL-1973)
Two component formulation enhances lipid mediated transfection efficiency
Optimized easy-to-use transfection protocol provided for transfection of siRNA, DNA, mRNA, and microRNA
Kit includes Transfection Enhancer reagent and recommended transfection protocol
Reproducible transfection results
- Download in vitro NTERA2 transfection protocol: [PDF]
- Download NTERA2 CRISPR/Cas9 transfection protocol: [PDF]
Download PowerPoint presentation for NTERA2 cells transfection kit: [PPT]
Developed and manufactured by Altogen Biosystems
Reagent exhibits at least 76% transfection efficiency of siRNA delivery. Transfection efficiency was determined by RT-PCR.
Transfection Protocol and MSDS:
Download Altogen Biosystems NTERA2 Transfection Protocol: [PDF]
Download MSDS: [PDF]
NTERA-2 Cell Line:
Embryonal carcinomas have proven to be invaluable models for studying the mechanisms that control differentiation of cells during embryogenesis in vitro. The NTERA-2 cell line is considered a well-characterized system of ectodermal differentiation. NTERA-2 cells can be used to study the early stages of human neurogenesis as they display developmental and biochemical properties similar to embryonic cells. The NTERA-2 cl.D1 cell line was established from the parental NTERA-2 cell line after a xenograft of a 22-year-old Caucasian male with malignant pluripotent embryonic carcinoma of the testis. This cell line has unique properties, making it useful for studying of certain types of testicular cancer. These cells exhibit high activity expression of N-myc oncogene. The cell line contains untreated cells with resistance to HCMV, and HIV-1. NTERA-2 cl.D1 exhibits an epithelial-like morphology, though there is more variety than in other cell lines due to the high differentiation of these cells. Altogen Biosystems manufactures lipid-based transfection kit optimized for NTERA-2 cells that can be utilized for both transient transfection and development of stable NTERA-2 cell lines and commonly used for life sciences laboratory research studies.
Cell line mutations:
Figure 1. siRNAs targeting Lamin A/C mRNA or non-silencing control siRNA were transfected into NTERA-2 cells following the recommended protocol. At 48 hours post-transfection the cells were analyzed by RT-PCR for Lamin A/C gene expression levels. 18S rRNA levels were used to normalize the Lamin A/C data. Values are normalized to untreated sample. Data are means ± SD (n=4).
Figure 2. Protein expression of Lamin A in NTERA-2 cells. DNA plasmid expressing Lamin A or siRNA targeting Lamin A were transfected into NTERA-2 cells following Altogen Biosystems transfection protocol. At 72 hours post-transfection the cells were analyzed by Western Blot for protein expression levels (normalized by total protein, 10 µg of total protein loaded per each well). Untreated cells used as a negative control.
Altogen Biosystems is a life sciences company that offers cell type-specific and optimized transfection products, electroporation kits, and in vivo delivery reagents. Advanced formulation of reagents and optimized transfection protocols provide efficient cellular delivery of protein, DNA, mRNA, shRNA and siRNA molecules. Read more about transfection technology at Altogen’s Transfection Resource.
Altogen Labs Research Services:
Altogen Labs provides GLP-compliant contract research studies for preclinical research, IND applications, and drug development. Biology CRO services include: xenograft models (90+), development of stable cell lines, ELISA assay development, cell-based and tissue targeted RNAi studies, safety pharm/tox assays, and other studies (visit AltogenLabs.com).
- 0.5 ml (Catalog #6875)
- 1.5 ml (Catalog #6876)
- 1.5 ml CRISPR (Catalog #2186)
- 8.0 ml (Catalog #7075)